SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial data from ...
Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026 SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE ...
(MENAFN- GlobeNewsWire - Nasdaq) Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026 SAN ...
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.
We have updated our Privacy Policy. Please review to learn more. By continuing to use our services, you agree to these updates. By Patty Nieberg Published May 6, 2026 ...
Daraxonrasib is an oral, multi-selective RAS inhibitor from Revolution Medicines Data from this trial previously prompted the Food and Drug Administration (FDA) to grant orphan drug designation to ...
After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more definitive step into the red-hot cancer field. The Chicago pharma has agreed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results